Gene expression analysis of cell death induction by Taurolidine in different malignant cell lines
By: Ansgar M Chromik, Stephan A Hahn, Adrien Daigeler, Annegret Flier, Daniel Bulut, Christina May, Kamran Harati, Jan Roschinsky, Dominique Sulberg, Dirk Weyhe, Ulrich Mittelkotter and Waldemar Uhl

BMC Cancer 2010, 10:595 doi:10.1186/1471-2407-10-595
Published: 30 October 2010

Abstract (Provisional)

Background

The anti-infective agent Taurolidine (TRD) has been shown to have cell death inducing properties, but the mechanism of its action is largely unknown. The aim of this study was to identify potential common target genes modulated at the transcriptional level following TRD treatment in tumour cell lines originating from different cancer types.

Methods

Five different malignant cell lines (HT29, Chang Liver, HT1080, AsPC-1 and BxPC-3) were incubated with TRD (100uM, 250uM and 1000uM). Proliferation after 8h and cell viability after 24h were analyzed by BrdU assay and FACS analysis, respectively. Gene expression analyses were carried out using the Agilent -microarray platform to indentify genes which displayed conjoint regulation following the addition of TRD in all cell lines. Candidate genes were subjected to Ingenuity Pathways Analysis and selected genes were validated by qRT-PCR and Western Blot.

Results

TRD 250uM caused a significant inhibition of proliferation as well as apoptotic cell death in all cell lines. Among cell death associated genes with the strongest regulation in gene expression, we identified pro-apoptotic transcription factors (EGR1, ATF3) as well as genes involved in the ER stress response (PPP1R15A), in ubiquitination (TRAF6) and mitochondrial apoptotic pathways (PMAIP1).

Conclusions

This is the first conjoint analysis of potential target genes of TRD which was performed simultaneously in different malignant cell lines. The results indicate that TRD might be involved in different signal transduction pathways leading to apoptosis.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.







Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements